News and Trends 4 Jan 2023
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
Infex Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted qualified infectious disease product (QIDP) designation to MET-X, the company’s broad spectrum metallo-beta-lactamase (MBL) inhibitor. Infex…
